Mark Toshner
Overview
Explore the profile of Mark Toshner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
96
Citations
7229
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rothman A, Villar S, Middleton J, Roussakis A, Varian F, Zafar H, et al.
Am J Respir Crit Care Med
. 2025 Mar;
PMID: 40080796
Rationale: Imatinib 400mg daily reduces pulmonary vascular resistance and improves exercise capacity in patients with pulmonary arterial hypertension. Concerns about safety and tolerability limit its use. Objectives: To identify a...
2.
Shergill S, Elshibly M, Hothi S, Parke K, England R, Wormleighton J, et al.
BMJ Open
. 2025 Mar;
15(3):e089508.
PMID: 40050066
Introduction: SARS-CoV-2 disease (COVID-19) has had an enormous health and economic impact globally. Although primarily a respiratory illness, multi-organ involvement is common in COVID-19, with evidence of vascular-mediated damage in...
3.
Ignatowicz A, Greenfield S, Gaddu P, Prince C, Toshner M, Robinson G, et al.
Health Technol Assess
. 2025 Feb;
:1-11.
PMID: 40013982
Background: Developing and implementing interventions that change clinical practice can be challenging and complex. Such interventions can be particularly difficult when attempting to change established behaviours and practices. While extensive...
4.
5.
Balistrieri A, De Bie E, Toshner M
Int J Cardiol Congenit Heart Dis
. 2024 Dec;
17:100523.
PMID: 39711778
Pulmonary hypertension (PH) encompasses a group of conditions which ultimately lead to elevated pulmonary arterial pressure. PH is classified into five subgroups, of which Group 1 pulmonary arterial hypertension (PAH),...
6.
Liley J, Bunclark K, Newnham M, Cannon J, Sheares K, Taboada D, et al.
Eur Respir J
. 2024 Nov;
65(3).
PMID: 39603669
Background: Risk prediction tools are routinely utilised in cardiothoracic surgery but have not been developed for pulmonary endarterectomy (PEA). There are no data on whether patients undergoing PEA may benefit...
7.
Elneima O, McAuley H, Leavy O, Chalmers J, Horsley A, Ho L, et al.
Int J Epidemiol
. 2024 Oct;
53(1).
PMID: 39429158
No abstract available.
8.
9.
Leavy O, Russell R, Harrison E, Lone N, Kerr S, Docherty A, et al.
ERJ Open Res
. 2024 Oct;
10(5).
PMID: 39351379
Background: In patients with coronavirus disease 2019 (COVID-19) requiring supplemental oxygen, dexamethasone reduces acute severity and improves survival, but longer-term effects are unknown. We hypothesised that systemic corticosteroid administration during...
10.
Chiu S, Bunclark K, Appenzeller P, Ghani H, Taboada D, Sheares K, et al.
J Heart Lung Transplant
. 2024 Sep;
44(1):25-32.
PMID: 39265669
Background: Previous studies have demonstrated the safety of pulmonary endarterectomy (PEA) across body mass index (BMI) strata. However, long-term survival and patient-reported outcome measures by BMI strata remain unknown. We...